LifeStance Reports Strong Q4 & FY25 Results, Returns to Profitability, and Announces $100M Share Repurchase Program

summarizeSummary

LifeStance Health Group reported robust financial results for the fourth quarter and full year 2025, marking a significant return to profitability for the full year. The company achieved double-digit revenue and Adjusted EBITDA growth, alongside a substantial increase in its clinician base and visit volumes. The positive momentum is expected to continue into 2026, with strong revenue and Adjusted EBITDA guidance. Furthermore, the Board's approval of a $100 million share repurchase program, representing approximately 3.6% of the current market capitalization, signals management's confidence in the company's financial health and commitment to returning capital to shareholders. This combination of strong performance, positive outlook, and a significant capital allocation decision makes the filing highly important for investors.

check_boxKey Events

• Return to Full-Year Profitability

  The company reported net income of $9.7 million for the full year ended December 31, 2025, a significant improvement from a net loss of $57.4 million in 2024.

• Strong Q4 and Full-Year 2025 Financial Performance

  Fourth quarter revenue increased 17% to $382.2 million, and full-year revenue grew 14% to $1,424.3 million. Adjusted EBITDA for Q4 rose 49% to $48.8 million, and for the full year, it increased 32% to $157.7 million.

• Positive 2026 Financial Guidance

  LifeStance expects full-year 2026 revenue between $1.615 billion and $1.655 billion, and Adjusted EBITDA between $185 million and $205 million, indicating continued growth.

• New $100 Million Share Repurchase Program

  The Board of Directors approved a share repurchase program authorizing the company to buy back up to $100 million of its common stock, reflecting strong cash generation and a healthy balance sheet.

auto_awesomeAnalysis

LifeStance Health Group reported robust financial results for the fourth quarter and full year 2025, marking a significant return to profitability for the full year. The company achieved double-digit revenue and Adjusted EBITDA growth, alongside a substantial increase in its clinician base and visit volumes. The positive momentum is expected to continue into 2026, with strong revenue and Adjusted EBITDA guidance. Furthermore, the Board's approval of a $100 million share repurchase program, representing approximately 3.6% of the current market capitalization, signals management's confidence in the company's financial health and commitment to returning capital to shareholders. This combination of strong performance, positive outlook, and a significant capital allocation decision makes the filing highly important for investors.